Novavax Is Missing Out on a Big Deal

Brian Orelli, PhD and Keith Speights, The Motley Fool
·4-min read

Novavax (NASDAQ: NVAX) hasn't set up a supply agreement for its coronavirus vaccine with the EU. In this video from Motley Fool Live, recorded on March 29, contributors Brian Orelli and Keith Speights discuss what might be taking so long and why this is truly a bid deal for Novavax. Brian Orelli: Moving on to Novavax, according to Reuters, the company is having some issues sourcing raw materials for its COVID-19 vaccine, which is causing it to delay setting up supply agreements with the European Union.